Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Anecortave acetate: a novel angiostatic steroid for the treatment of ocular neovascular diseases

Aug. 4, 1999

Beta-blocker proxodolol, a safe and effective treatment for glaucoma

Aug. 4, 1999

Travoprost is safe and effective in treating elevated IOP in glaucoma patients

Aug. 3, 1999

Allergan profiles its Ocular Hypotensive Lipids at SOE 1999

Aug. 3, 1999

Alcon describes therapeutic potential of ocular antiinflammatory agents

Aug. 3, 1999

Acadia licenses novel leads for glaucoma therapy to Allergan

July 30, 1999

New muscarinic compounds from Alcon especially useful for Rx of glaucoma

July 29, 1999

New agents for glaucoma disclosed by Alcon in recent patent literature

July 27, 1999

Sunrise LTK System not recommended for FDA approval

July 26, 1999

Alcon's new prostaglandin analogues for glaucoma

July 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.